CA2724525A1 - Antagonistes de bmp9 et bmp10, alk1 et autres ligands alk1, et leurs utilisations - Google Patents

Antagonistes de bmp9 et bmp10, alk1 et autres ligands alk1, et leurs utilisations Download PDF

Info

Publication number
CA2724525A1
CA2724525A1 CA2724525A CA2724525A CA2724525A1 CA 2724525 A1 CA2724525 A1 CA 2724525A1 CA 2724525 A CA2724525 A CA 2724525A CA 2724525 A CA2724525 A CA 2724525A CA 2724525 A1 CA2724525 A1 CA 2724525A1
Authority
CA
Canada
Prior art keywords
alki
bmp9
antibody
agent
alk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2724525A
Other languages
English (en)
Inventor
Jasbir Seehra
John Knopf
Robert S. Pearsall
Asya Grinberg
Ravindra Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA2724525A1 publication Critical patent/CA2724525A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2724525A 2008-05-15 2009-05-15 Antagonistes de bmp9 et bmp10, alk1 et autres ligands alk1, et leurs utilisations Abandoned CA2724525A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5364408P 2008-05-15 2008-05-15
US61/053,644 2008-05-15
PCT/US2009/003016 WO2009139891A2 (fr) 2008-05-15 2009-05-15 Antagonistes de bmp9 et bmp10, alk1 et autres ligands alk1, et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2724525A1 true CA2724525A1 (fr) 2009-11-19

Family

ID=40886532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724525A Abandoned CA2724525A1 (fr) 2008-05-15 2009-05-15 Antagonistes de bmp9 et bmp10, alk1 et autres ligands alk1, et leurs utilisations

Country Status (3)

Country Link
EP (1) EP2291401A2 (fr)
CA (1) CA2724525A1 (fr)
WO (1) WO2009139891A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518218A (zh) 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
MX2010011998A (es) * 2008-05-02 2011-04-11 Acceleron Pharma Inc Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar.
US20160228509A9 (en) * 2009-05-08 2016-08-11 Novartis Ag Diagnostic BioMarkers for Fibrotic Disorders
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113590A2 (fr) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Propeptides de bmp10 et procédés correspondants
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
EA201300320A1 (ru) * 2005-09-07 2014-02-28 Эмджен Фримонт Инк. Моноклональные антитела человека к киназе-1, подобной рецептору активина
CN111518218A (zh) * 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
ES2554812T3 (es) * 2007-11-09 2015-12-23 Genentech, Inc. Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
MX2010011998A (es) * 2008-05-02 2011-04-11 Acceleron Pharma Inc Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar.

Also Published As

Publication number Publication date
WO2009139891A3 (fr) 2010-02-18
EP2291401A2 (fr) 2011-03-09
WO2009139891A2 (fr) 2009-11-19

Similar Documents

Publication Publication Date Title
AU2019232838B2 (en) Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
US20220296708A1 (en) Alk1 receptor and ligand antagonists and uses thereof
US9452197B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
CA2724525A1 (fr) Antagonistes de bmp9 et bmp10, alk1 et autres ligands alk1, et leurs utilisations
US20220017600A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
AU2018279010B2 (en) ALK1 receptor and ligand antagonists and uses thereof
AU2014200003A1 (en) ALK1 receptor and ligand antagonists and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140514

FZDE Dead

Effective date: 20190515